Marks Group Wealth Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.54M Buy
10,307
+7,590
+279% +$1.93M 0.22% 113
2026
Q2
$818K Buy
2,717
+1,067
+65% +$322K 0.07% 220
2026
Q1
$546K Buy
+1,650
New +$561K 0.05% 236

Other funds holding ALNY

Marks Group Wealth Management's ALNY Position: Q3 2026 in Review

Marks Group Wealth Management increased its Alnylam Pharmaceuticals (ALNY) stake by 279% in Q3 2026, buying an estimated $1.93M and bringing the position to 10,307 shares worth $2.54M. The position accounts for 0.22% of the portfolio, ranked #113.

Marks Group Wealth Management first reported a position in ALNY in Q1 2026 and has held it in 3 quarters since. 591 funds tracked by Wall St. Rank hold ALNY as of Q3 2026.

  • Marks Group Wealth Management held 10,307 shares of Alnylam Pharmaceuticals worth $2.54M as of Q3 2026.
  • Marks Group Wealth Management bought 7,590 Alnylam Pharmaceuticals shares in Q3 2026, an estimated $1.93M.
  • Alnylam Pharmaceuticals made up 0.22% of Marks Group Wealth Management's portfolio in Q3 2026, its #113 holding.
  • Marks Group Wealth Management first reported a position in Alnylam Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 591 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2026.

Based on Marks Group Wealth Management's 13F filing for Q3 2026, filed 5 Nov 2026.